24results about How to "Enhance cell viability" patented technology

The invention provides an in-vitro culture method of T cells, and belongs to the technical field of genetic engineering.The culture method comprises the steps that immune cell serum-free culture media are added into peripheral blood mononuclear cells, and activated culture is conducted in the presence of cell factors to obtain activated T cells; the cell factor comprises an IL-2 monoclonal antibody and a CD3 monoclonal antibody, and further comprises two or three of an iCAM1 protein, a CCL21 protein and OK432. The T cells obtained through activation and multiplication culture are relatively stable in cell phenotype, relatively large in amplification multiple, relatively high in cell viability and relatively high in tumor killing efficiency. T cells are obtained after activation is performed for 24 hours and then multiplication culture is performed for 14 days, and the number of the cells is 6.2-8.9 * 10 < 9 >; the killing rate on Hela cells is 51.9 to 74.1 percent, and the killing rate on LOVO cells is 55.7 to 80.5 percent.

The application belongs to the field of biological medicine, and discloses a culture medium, which comprises a basic culture medium, and the basic culture medium is added with ITS-A: 1x, arginine: 15-20 mu g / ml, SPP1: 3-5 mu g / ml and S100A9: 3-5 mu g / ml. The culture medium is particularly suitable for microtumor culture of MTC model and has good cell viability. Meanwhile, the application also provides application of the culture medium and a microtumor culture method.

The invention relates to the technical field of polypeptides, and mainly relates to a polypeptide with a repairing effect and application thereof. The polypeptide contains the following amino acid sequence: (EVDEQMLNVQNK) n, wherein n is any one natural number from 3 to 10. The polypeptide can significantly improve the activity and proliferation of keratinocytes, and has an excellent effect of promoting skin repair.

The invention relates to the technical field of hydrogel application, in particular to a photopolymerization rapid prototyping transparent medical hydrogel application and a preparation method thereof. The invention discloses a transparent medical hydrogel patch capable of being rapidly formed through photopolymerization. The transparent medical hydrogel patch comprises hydrogel, the hydrogel is prepared by the following steps: coating a release film with a pre-polymerization liquid containing ultraviolet light activity, and carrying out polymerization molding through ultraviolet light irradiation. According to the transparent medical hydrogel patch, vinyl monomers serve as raw materials, the hydrogel patch is prepared in a coating mode, the problem that leveling is difficult when the hydrogel patch is injected into a mold is solved, continuous batch production can be carried out, the hydrogel patch can be completely formed only by 5-15 s of UV polymerization time, and the light polymerization efficiency is remarkably improved.

Provided is a method for modifying a cell, which comprises the following steps: transfecting a target molecule and a screening marker molecule to a cell in a non-viral manner, so that the cell expresses the target molecule and the screening marker molecule. Also provided is a modified cell obtained using the method. The method can effectively enrich the desired cell and increase cell positivity with respect to the target molecule.

The present disclosure relates to microorganisms comprising a protein encoded by an exogenous ftsN gene, and methods of producing L-amino acids using the same.

Provided herein are methods for inactivating effector cells (e.g., NK cells, including cells as spot type cells for adoptive cell therapy). The inactivated cells can be cryopreserved after inactivation. The inactivated cells may be expanded and / or activated prior to inactivation, and may or may not include a transgene, which may optionally encode a chimeric antigen receptor and / or a T cell receptor. In certain embodiments, disclosed are methods for inactivating NK cells comprising treating with an inactivating agent, which is a kinase inhibitor, such as an mTOR inhibitor, and / or a tyrosine kinase inhibitor, such as rapamycin and / or dasatinib. Also provided herein are inactivated and cryopreserved NK cells, and methods of making and / or using the same for treating a subject in need thereof (e.g., treating a subject having cancer).

The invention discloses a culture medium and a method for culturing digestive tract tumors by using a three-dimensional tumor chip technology. The culture medium is prepared from the following components: 5-10% v / v of FBS, 20-30% v / v of a Ham's F12 nutrient solution, 0.10-0.15 ng / mL of a recombinant human epidermal growth factor (EGF), 20-30 ng / mL of hydrocortisone, 0.05-0.15 nM of cholera toxin, 4-6 g / mL of insulin, 9-11 M of Y-27632 dihydrochloride, 10-30 [mu] g / mL of cefoperazone sodium, 5-15 [mu] g / mL of sulbactam sodium and the balance of DMEM (Dulbecco Modified Eagle Medium). The culture medium not only reduces the pollution rate, but also is high in cell activity and has an immune microenvironment similar to that of an original tissue, so that it is possible that an in-vitro 3D-TSCs culture method evaluates the drug sensitivity of immunotherapy drugs for clinical digestive tract tumors, and the culture medium has very high clinical application value and market potential.

The invention provides an application of RARRES1 in diagnosis and treatment of retinal injury diseases. It is found for the first time that the RARRES1 is significantly down-regulated in the neovascular age-related macular degeneration, and overexpression of the RARRES1 can significantly inhibit apoptosis of ARPE-19 cells under H2O2 conditions and improve the cell viability of ARPE-19, provides a new direction for diagnosis and effective treatment of the neovascular age-related macular degeneration, and has a wide application prospect.

The invention relates to the technical field of medical health care products, in particular to an anticancer composition containing phellinus igniarius extract and total ginsenoside and application of the anticancer composition. The anticancer composition comprises a phellinus igniarius extract and total saponins of ginseng. The mass ratio of the phellinus igniarius extract to the total ginsenoside is 1: (0.5-2); the phellinus igniarius extract is obtained by taking artificially cultivated phellinus igniarius as a raw material through ultrasonic-assisted extraction and reflux extraction in stages; the extraction solvent is selected from water or an ethanol water solution with the ethanol concentration not exceeding 40%. The anticancer composition provided by the invention has remarkable in-vitro anticancer activity and low toxicity to normal cells.

The present invention provides an in vitro culture method of T cells, which belongs to the field of genetic engineering technology. The culture method is to add immune cell serum-free culture medium to peripheral blood mononuclear cells, and perform activation culture in the presence of cytokines to obtain activated T cells; the cytokines include IL-2, CD3 monoclonal antibodies, and two or three of iCAM1 protein, CCL21 protein, and OK432. The T cells obtained by the activation and amplification culture of the present invention have a relatively stable cell phenotype, a large amplification multiple, a high cell viability, and a high tumor killing efficiency. The T cells obtained by the present invention after activation for 24 hours and then amplification culture for 14 days have a cell number of 6.2-8.9×10 9 cells; the killing rates for Hela cells were 51.9-74.1%, and for LOVO cells were 55.7-80.5%.

This invention provides a kit, method, and single-cell library construction method for the dissociation of marine animal tissues. The dissociation method includes: S1) dissociating marine animal tissue samples at 8℃~12℃ using a cell dissociation buffer to obtain a single-cell suspension; S2) centrifuging the single-cell suspension and washing the single-cell precipitate obtained after centrifugation with a cell resuspension buffer to obtain single cells from the marine animal tissue sample; wherein, the cell dissociation buffer comprises a protease; the protease is Bacillus subtilis protease A; the concentration of sodium ions in the cell resuspension buffer is 300-800mM, and the concentration of potassium ions is 5-20mM.

The present invention relates to a composition for cryoprotection, the composition comprising: a nucleic acid structure comprising a scaffold nucleic acid that folds at a predetermined position and forms a plurality of chains, and a plurality of staple nucleic acids that form a double strand by binding to at least one of the chains and at least a portion of which has a complementary sequence to the scaffold nucleic acid; a linker bound to at least a portion of the nucleic acid structure; and a peptide bound to at least a portion of the linker, wherein the composition can increase cell viability during cryopreservation of cells and tissues and allows the texture of the food to be maintained when used for frozen food.

This invention provides a benzothiadiazine 1,1-dioxide compound, its preparation method, and its applications. The general structural formula of the benzothiadiazine 1,1-dioxide compound is shown in Formula (I), or its isomers, or pharmaceutically acceptable salts, esters, or prodrugs thereof. The benzothiadiazine 1,1-dioxide compound of this invention has a novel structure, can selectively inhibit HDAC6 enzyme, has a strong protective effect on nerve cells, low toxicity, and low potential cardiotoxicity, and is expected to be used as a neuroprotective agent for the treatment of neurodegenerative diseases.

The invention belongs to the field of medicines, and discloses an activity detection method of a stress-induced mesenchymal stem cell extract, which comprises the following steps: pre-culturing BV2 cells, preparing more than three groups of mesenchymal stem cell extract culture mediums with different concentrations, and detecting the anti-inflammatory performance of the mesenchymal stem cell extract. Wherein the model group and the drug delivery group are established, lipopolysaccharide induced inflammation stimulation is performed on BV2 cells in the model group and the drug delivery group, then the BV2 cells are respectively transferred to a corresponding blank culture medium and a culture medium containing a mesenchymal stem cell extract for incubation, and finally BV2 cell culture supernate is taken for Elisa detection to obtain the concentration of inflammatory factors. According to the detection method disclosed by the embodiment of the invention, a safe experimental concentration and a data result with good repeatability and significance can be screened out, a performance monitoring model of the mesenchymal stem cell extract can be established, the product quality can be stabilized, the change rule of the product concentration and the anti-inflammatory activity can be explored, and a basis is established for subsequently using the mesenchymal stem cell extract as an inflammation inhibitor.

The present invention discloses a lipid complex for mammalian cell culture medium and its preparation method and application, belonging to the field of cell culture technology. The lipid complex includes lipid substances, organic solvents, solubilizers and water prepared in a certain proportion; the lipid substances include one or more of α-linolenic acid, γ-linolenic acid, oleic acid, linoleic acid, eicosapentaenoic acid, docosahexaenoic acid, myristic acid, lauric acid, arachidonic acid and palmitic acid. The lipid complex of the present invention not only has clear chemical composition and is safe and harmless, but also has a simplified formula and excellent performance. It can effectively increase cell growth density and cell viability and increase the yield of target protein when added to the culture medium, and has broad application value.

The application belongs to the technical field of biological medicine, and particularly relates to a thymus tissue dissociation reagent, a kit and application thereof in obtaining thymus epithelial cells. The thymus tissue dissociation reagent at least comprises collagenase D, dispersinase II, deoxyribonuclease I, dissociation enzyme and a dissolving reagent; and collagenase II and / or collagenase IV and / or trypsin. The cell survival rate of the thymus tissue dissociation reagent after dissociating the thymus tissue is maintained at a high level of 95.7% to 99.6%, which is significantly higher than that of the prior art; and after sorting, the number of thymus epithelial cells enriched and obtained from each gram of thymus tissue is 1.38e 5 ~1.06e 6 , and the success rate of enriching and obtaining thymus epithelial cells is as high as 95%, which is significantly higher than that of the prior art; and the proportion of epithelial stem cells in the thymus epithelial cells is 65.7%, which is significantly higher than that of the prior art.

The invention relates to a preparation method and application of a respiratory tract sample single-cell suspension. The method comprises the following steps: putting a fresh respiratory tract sample into a sterile collection bottle; adding a Dulbecco improved Eagle culture medium until the volume is 5-30ml, then adding a liquefying agent for liquefying, and liquefying in a water bath at the temperature of 30-40 DEG C for 10-30 minutes; centrifuging, and absorbing and discarding the supernatant; adding a mild cell digestive enzyme to resuspend the cells, and incubating to obtain a cell suspension; filtering is performed; centrifuging, and absorbing and discarding the supernatant; dMEM and 9-11% of fetal calf serum are added to resuspend the cells, and a single-cell suspension is obtained.

The invention discloses an application of marine-derived alkaloid in preparation of an anti-cholestasis medicine, and belongs to the field of natural medicines. The invention discloses an application of indolediketopiperazine alkaloid 12R, 13S-Dihydroxyfumitorgin C (DHFC) or a pharmaceutically acceptable salt of the indolediketopiperazine alkaloid in preparation of an agonist of a peroxisome proliferator-activated receptor delta (PPAR delta), and an application of the indolediketopiperazine alkaloid 12R, 13S-Dihydroxyfumitorgin C (DHFC) or the pharmaceutically acceptable salt of the indolediketopiperazine alkaloid in preparation of an anti-cholestasis medicine, and the indolediketopiperazine alkaloid 12R, 13S-Dihydroxyfumitorgin C (DHFC) or the pharmaceutically acceptable salt of the indolediketopiperazine alkaloid has a protective effect on cholestasis by activating the PPAR delta. DHFC is in high-affinity binding with an LBD region of PPAR delta, the transcriptional level of downstream genes of PPAR delta is increased, the affinity KD of DHFC to PPAR delta protein is 153nM, and the DHFC plays a synergistic treatment role in multiple links of improving bile acid homeostasis, inhibiting inflammation, relieving liver fibrosis and the like. The invention provides a new lead compound for the development of anti-cholestasis drugs, and has important significance for the development of Chinese marine-derived drugs. Formula (I)

The application discloses a kind of pyranose derivatives represented by the following general formula I, its stereoisomer, pharmaceutically acceptable salt, crystalline hydrate or solvate, its preparation method, the pharmaceutical composition for protecting the compounds and its application in central nervous system diseases and inflammatory diseases etc..According to the pyranose derivative of the application, the cell viability of A beta 1-42 induced cell damage model is significantly improved, the cell viability of 6-hydroxydopamine induced cell damage model is improved, the cell viability of oxygen-glucose deprivation / reoxygenation cell damage model is improved, the level of lipopolysaccharide induced cell inflammatory factor is inhibited, etc.The pharmacological effects have good clinical application prospect.

The present application belongs to the field of biomedical and cosmetic technology, and particularly relates to the application of protein AMBP in the preparation of a preparation for promoting the activity of hair follicle cells or for preventing and treating alopecia. The present application first discovers that the protein AMBP has the activity of regulating the hair follicle hair papilla cells, hair matrix cells and outer root sheath cells, can promote the proliferation of the hair papilla cells, the hair matrix cells and the outer root sheath cells, and improve the ability of the outer root sheath cells to remove active oxygen; also has the effects of promoting the hair follicle cycle transition, promoting hair growth and hair thickening. Therefore, the protein AMBP can be applied to the preparation of a preparation for treating alopecia.

This invention belongs to the field of traditional Chinese medicine technology, specifically relating to a food-medicine homology composition and its use in the preparation of a treatment for lung injury. The food-medicine homology composition of this invention comprehensively considers the overall state of the body and the intrinsic physiological functions of the lungs. Its main active ingredients are lung-protecting food-medicine homology materials and small-molecule collagen peptides. Specifically, *Siraitia grosvenorii* (monk fruit) and *Lilium brownii* (lily bulb) are the principal ingredients, while *Eriobotrya japonica* (loquat leaf), *Platycodon grandiflorus* (platycodon root), *Lonicera japonica* (honeysuckle flower), and *Morus alba* (mulberry leaf) are the assistant ingredients. The adjuvant ingredients include *Dioscorea opposita* (Chinese yam), *Codonopsis pilosula* (codonopsis root), *Astragalus membranaceus* (astragalus root), *Pyrus pyrifolia* (snow pear), *Tremella fuciformis* (white fungus), and olive. These ingredients have the effects of clearing heat and moistening the lungs, invigorating qi and strengthening the spleen, and nourishing yin and moistening dryness. Combined with small-molecule collagen peptides, it comprehensively regulates lung tissue, helps improve lung function, promotes lung repair, and achieves lung-protecting effects, making it suitable for the treatment of lung injury.

The present invention relates to an embryoid body digestion solution and its application in isolating hematopoietic stem cells. Specifically, the present invention provides a digestion solution suitable for embryoid body dissociation, comprising two components, collagenase and dispase, which has a synergistic effect on the dissociation or digestion of embryoid bodies, and can efficiently dissociate embryoid bodies into single cells in a short time, and the obtained single cells can maintain a high cell viability, good cell phenotype and diversity of cell groups, which can be used for subsequent research or sorting target cells, such as obtaining hematopoietic stem cells. The present invention also provides a method and application for digesting embryoid bodies, which has broad application prospects.

The present invention relates to a method for preparing bone marrow-derived endothelial progenitor cells having increased vasculogenesis by using PDGF-BB, and a method for preparing a cell therapeutic agent for treating anangioplasia-related diseases by using the method. Particularly, the present invention relates to: a method for preparing endothelial progenitor cells having increased vasculogenesis, comprising a step of treating isolated endothelial progenitor cells with PDGF-BB and culturing same; a composition for stimulating vasculogenesis, comprising endothelial progenitor cells and PDGF-BB as active ingredients; a method for preparing a cell therapeutic agent for treating anangioplasia-related diseases, comprising a step of mixing isolated endothelial progenitor cells, mesenchymal stem cells and PDGF-BB; and a cell therapeutic agent for treating anangioplasia-related diseases, prepared by the method.